Source comparison
Best Growth Hormone Secretagogue Peptides 2026: Mechanism Comparison
The following table compares the top growth hormone secretagogues used in 2026 research protocols, organized by receptor pathway, pharmacokinetics, and practical considerations for study design. Sermorelin GHRH receptor agonist 10–20 minutes 200–500mcg SC dail
This comparison does not assign a generated winner or score.
- The following table compares the top growth hormone secretagogues used in 2026 research protocols, organized by receptor pathway, pharmacokinetics, and practical considerations for study design.
- Sermorelin
- GHRH receptor agonist
- 10–20 minutes
- 200–500mcg SC daily before bed
- Acute pulsatile GH studies; natural secretion modeling
- Gold standard for physiological GH pulses but requires daily administration
- CJC-1295 No DAC (Mod GRF)
- ~30 minutes
- 100–200mcg SC 1–3x daily
- Combined with ghrelin mimetics for synergistic GH release
- Most commonly stacked with ipamorelin for robust, reproducible pulses
- CJC-1295 With DAC
- 6–8 days
- 1–2mg SC weekly
- Long-term GH elevation studies; convenience protocols
- Sustained release ideal for chronic studies but diverges from natural pulsatility
- Ipamorelin
- Ghrelin receptor agonist (GHS-R1a)
- ~2 hours
- 200–300mcg SC 1–3x daily
- Selective GH stimulation; minimal cortisol/prolactin effects
- Most selective ghrelin mimetic—preferred for clean GH isolation
- GHRP-2
- Ghrelin receptor agonist
- 100–300mcg SC 1–3x daily
- High-amplitude GH pulses; appetite-neutral studies
- Potent GH release with moderate selectivity—slight cortisol elevation
- GHRP-6
- Cachexia models; appetite stimulation research
- Strong GH response but pronounced appetite stimulation limits applicability
- Hexarelin
- ~70 minutes
- 100–200mcg SC 1–2x daily
- Most potent GH release per mcg
- Receptor desensitization after 4–8 weeks limits chronic use
- Tesamorelin
- 2mg SC daily
- Visceral adipose reduction; lipodystrophy models
- Only FDA-approved GH secretagogue; best-studied for fat loss endpoints
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- 24+ hours
- 10–25mg oral daily
- Sustained GH/IGF-1 elevation; convenience protocols
- Only oral secretagogue—ideal for long-term studies without injections
- This comparison demonstrates that no single peptide is universally 'best'—selection depends entirely on whether the research prioritizes pulsatile versus sustained GH, injection frequency tolerance, appetite effects, or specific metabolic endpoints. Tesamorelin leads for visceral fat studies, ipamorelin for clean GH selectivity, and MK-677 for oral convenience.